This document is a published patent application from the USPTO, not a regulatory rule or guidance. It describes a novel method for differentiating pluripotent stem cells (PSCs) into CD34+ hematopoietic precursor cells, which can then be used to generate natural killer (NK) cells and other terminally differentiated hematopoietic cells. The method involves using a specific hemogenic endothelium induction cocktail that includes a WNT signaling pathway activator, a bone morphogenetic protein, and/or a vascular endothelial growth factor.

While patent applications do not impose direct compliance obligations on regulated entities, they represent potential future innovations and intellectual property in the biotechnology and pharmaceutical sectors. Companies involved in stem cell research, cell therapy development, or the manufacturing of immune cells should be aware of this application as it may influence future research directions, licensing opportunities, or competitive landscapes. No immediate actions are required from compliance officers based on this publication, but it warrants monitoring for potential future patent grants and their implications.